Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07572357

Clinical Evaluation of the RH210 Hearing Aid

The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss. The purpose of this clinical investigation is to generate objective and subjective evidence of the clinical performance and safety of the device.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hearing Impairment, Sensorineural Ear Diseases Hearing Disorders Hearing Loss Hearing Loss, Sensorineural Nervous System Diseases Neurologic Manifestations Otorhinolaryngologic Diseases Pathological Conditions, Signs and Symptoms Perceived Hearing Loss Sensation Disorders Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Acoustic Laboratories

Macquarie Park, New South Wales, Australia

Location status: Recruiting

Location contact

Bettina Turnbull, AuD

CONTACT

[email protected]

Bettina Turnbull, AuD

PRINCIPAL_INVESTIGATOR

About this study

The primary objective of this clinical investigation is to demonstrate that the RH210A device provides a clinically meaningful improvement in speech understanding in noise compared with unaided listening in adults with perceived mild-to-moderate hearing loss.

Speech-in-noise performance will be assessed using the BKB-SIN (Australian version), which quantifies the change in signal-to-noise ratio required for sentence recognition. The primary endpoint is defined as the within-subject difference between unaided and RH210 conditions (change in SNR = Unaided - RH210). A successful outcome is defined as a mean improvement of equal to or more than 2 dB in SNR with RH210 compared to unaided listening.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

Exclusion criteria

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

Treatment and study plan

Investigational device (RH210A)

Device

Over the counter device

Apple AirPods Pro (2nd Generation) with Hearing Aid Feature (HAF)

Device

FDA cleared OTC device (Control arm)

Primary outcomes

  1. Aided vs unaided pure-tone audiogram (PTA) measured in dBSPL

    Time frame: Day 1 (Visit 1) and Day 7 (Visit 2)

    Aided audiogram with both the investigational and control device measured at 500, 1000, 2000 and 4000Hz in dBSPL. Compared with unaided audiogram measured at the same frequencies in dBSPL. Measured conducted in the sound field in a sound isolated room with warble tones presented from 0 degrees azimuth.

Secondary outcomes

  1. Speech understanding in background noise (BKB-SIN; AUS)

    Time frame: Day 1 (Visit 1) and Day 7 (Visit 2)

    Participants will be asked to perform a speech in noise test. Participants will be presented with speech sentences and asked to recall the words they hear. The target stimuli will comprise of BKB sentences (Australian English version), and the noise will be spatially diffuse speech babble. The noise level will be fixed and the speech level will be adaptively changed (Keidser et al, 2013) to determine the speech reception threshold at 50% in dB SNR recall performance, using phonemic scoring. The test conditions, unaided and aided, will comprise of four repeated measures each, with 32 sentence repeats, conducted at 50% threshold. The order of conditions will be randomized across participant. The device will be set to 'Immersive Conversation' mode.

    For the AirPods Pro 2, the Hearing Aid setting will be toggled, and the AirPods set in Transparency mode.

  2. Real Ear Measure Measurement (REIG)

    Time frame: Day 1 (Visit 1) and Day 7 (Visit 2)

    Measurement of the Real Ear Insertion Gain (REIG) for the control and intervention device. Output will be compared with the prescribed NAL-R target values.

  3. Moderated walk to evaluate simulated "real world benefit" (Ecological Momentary Assessment (EMA): NAL Australia).

    Time frame: Day 1 (Visit 1) and Day 7 (Visit 2)

    Participants will use the to use the devices in a controlled, moderated, 60 minute walk. The walk will cover five key listening environments and :

    • Library (~40 dBA) very low or no noise
    • Office (~50 dBA) with low level noise
    • Outdoor parkway (~55 dBA) with environmental noise
    • Traffic / street (~70-75 dBA) with traffic noise
    • Café / food court (~65-70 dBA) with multi-talker babble noise Performance will be evaluated using the Ecological Momentary Assessment (EMA) (NAL Australia). The study participants will provide feedback by selecting a rating on a five-point Likert scale for questions related to subjective impressions for speech intelligibility, listening effort, loudness/comfort and their aided/unaided preference while using the trial device or control device during the moderated walk.

Other outcomes

  1. Usability of RH210 using the System Usability Survey (SUS: NAL)

    Time frame: Day 1 (Visit 1) and Day 7 (Visit 2)

    Assess the subjective usability of the RH210 hearing aid software and application workflow in real-world use using the System Usability Survey (SUS) from the National Acoustic Laboratory (NAL). This is to gather data for a proposed human factors evaluation.

    The scoring is

    • Poor: Scores below 51 are considered poor.
    • Average Score: 68.
    • Above Average: > 68.
    • Below Average: < 68.
    • Good/Excellent: Scores over 79 are considered good, while 80.3 or higher is an A grade.

Study contacts

Contact information is provided by the study sponsor or research team.

Marisa Poulos, Master of Audiology

CONTACT

[email protected]

+61 2 9412 6872

Sanna Hou, Master of Audiology

CONTACT

[email protected]

+61 2 9412 6872

Sponsors and collaborators

Lead sponsor

Rehear Audiology Company LTD

Industry

Collaborators

  • Global Edge Medtech Consulting
  • National Acoustic Laboratories

Registry information

Official study title

Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 7, 2026
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.